1. American Diabetes Association. Standard of medical care in diabetes – 2015. Diabetes Care. 2015; 38: S4-S69.
2. The American Heart Association and American Stoke Association. Guidelines for the primary prevention of stoke: A guideline for healthcare professional. Stoke. 2011; 42: 517-584.
3. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c independent risk factor for diabetic complications. JAMA. 2006; 295: 1707-1782. doi: 10.1001/jama.295.14.1707
4. Hirsch IB, Brownlee M. Should minimal blood glucose variability become the gold standard of glycemic control? J Diabetes Complications. 2005; 19: 178-181. doi: 10.1016/j.jdiacomp.2004.10.001
5. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. The Diabetes Control and Complication Trial Research Group. N Engl J Med. 1993; 329: 977-986. doi: 10.1056/NEJM199309303291401
6. The relationship of glycemic exposure (hba1c) to the risk of development and progression of retinopathy in the diabetes control and complication trail. The Diabetes Control and Complications Trial Research Group. Diabetes. 1995; 44: 968-983.
7. The diabetes control and complication trail/epidemiology of diabetes interventions and complication research group. Effect of intensive therapy on the microvascular complication of type 1 diabetes mellitus. JAMA. 2002; 287: 2563-2569. doi: 10.1001/jama.287.19.2563
8. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008; 358: 2545-2559. doi: 10.1056/NEJMoa0802743
9. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008; 358: 2560-2572. doi: 10.1056/ NEJMoa0802987
10. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009; 360: 129-139. doi: 10.1056/NEJMoa0808431
11. Cavalot F. Do data in the literature indicate that glycaemic variability is a clinical problem? Glycaemic variability and vascular complications of diabetes. Diabetes Obes Metab. 2013: 15: 3-8. doi: 10.1111/dom.12140
12. Muggeo M, Verlato G, Bonora E, et al. Long-term instability of fasting plasma glucose predicts mortality in elderly NIDDM patients: the Verona Diabetes Study. Diabetologia. 1995; 38: 672-679. doi: 10.1007/BF00401838
13. Muggeo M, Verlato G, Bonora E, Zoppini G, Corbellini M, de Marco R. Long-term instability of fasting plasma glucose, a novel predictor of cardiovascular mortality in elderly patients with non-insulin-dependent- diabetes mellitus: the Verona Diabetes Study. Circulation. 1997; 96: 1750-1754. doi: 10.1161/01.cir.96.6.1750
14. MuggeoM, Zoppini G, Bonora E, et al. Fasting plasma glucose variability predicts 10-year survival of type 2 diabetes patients: the Verona Diabetes Study. Diabetes Care. 2000; 23: 45-50. doi: 10.2337/diacare.23.1.45
15. Zoppini G, Verlato G, Targher G, et al. Variability of body weight, plus pressure and glycaemia strongly predict total mortality in elderly type 2 diabetic patients. The Verona Diabetes Study. Diabetes Metab Res Rev. 2008; 24: 624-628. doi: 10.1002/dmrr.897
16. MuggeoM, Verlato G, Bonora E, et al. The Verona Diabetes Study: a population-based survey on known diabetes mellitus prevalence and 5-year all-cause mortality. Diabetologia. 1995; 38: 318-325. doi: 10.1007/BF00400637
17. Lin CC, Li CI, Yang SY, et al. Variation of fasting plas- ma glucose: a predictor of mortality in patients with type 2 diabetes. Am J Med. 2012; 125: 416. e9-e18. doi: 10.1016/j. amjmed.2011.07.027
18. Lin CC, Li CI, Liu CS, et al. Annual fasting plasma glucose variation increases risk of cancer incidence and mortality in patients with type 2 diabetes: The Taichung Diabetes Study. Endocr Relat Cancer. 2012; 19: 473-483. doi: 10.1530/ERC-12- 0038
19. Lin CC, Yang CP, Li CI, et al. Visit-to-visit variability of fasting plasma glucose as predictor of ischemic stroke: competing risk analysis in a national cohort of Taiwan Diabetes Study. BMC Med. 2014; 12: 165. doi: 10.1186/s12916-014-0165-7
20. Siegelaar S, Holleman F, Hoekstra J, DeVries JH. Glucose variability; Does it matter? Endocrine Rev. 2010; 31: 171-182. doi: 10.1210/er.2009-0021
21. Service FJ, O’Brien PC. The relation of glycaemia to the risk of development and progression of retinopathy in the Diabetic Control and Complications Trial. Diabetologia. 2001; 44: 1215-1220. DOI: 10.1007/s001250100635
22. Molnar GD, Taylor WF, Ho MM. Day-to-day variation of continuously monitored glycaemia: a further measure of diabetic instability. Diabetologia. 1972; 8: 342-348. doi: 10.1007/BF01218495
23. Eslami S1, Taherzadeh Z, Schultz MJ, Abu-Hanna A. Glucose variability measures and their effect on mortality: a systematic review. Intensive Care Med. 2011; 37: 583-593. doi: 10.1007/s00134-010-2129-5
24. Ceriello A, Ihnat MA. Glycemic variability: a new therapeutic challenge in diabetes and the critical care setting. Diabet Med. 2010; 27: 862-867. doi: 10.1111/j.1464-5491.2010.02967.x
25. Risso A, Mercuri F, Quagliaro L, DamanteG, Ceriello A. Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture. Am J Physiol Endocrinol Metab. 2001; 281: E924-E930. doi: 10.1152/ajpendo.2001.281.5.E924
26. Del Guerra S, Grupillo M, Masini M, et al. Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose. Diabetes Metab Res Rev. 2007; 23: 234-238. doi: 10.1002/dmrr.680
27. Quagliaro L, Piconi L, Assaloni R, Martinelli L, MotzE, Ceriello A. Intermittent high glucose enhances apoptosis related to oxidative stress in human umbilical vein endothelial cells: the role of protein kinase C and NAD(P)H-oxidase activation. Diabetes. 2003; 52: 2795-2804. doi: 10.2337/diabetes.52.11.2795
28. Piconi L, Quagliaro L, Da Ros R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1, Eselectin and interleukin-6 expression in human umbilical endothelial cells in culture: the role of poly(ADP-ribose) polymerase. J Thromb Haemost. 2004; 2: 1453-1459. doi: 10.1111/j.1538-7836.2004.00835.x
29. Quagliaro L, Piconi L, Assaloni R, et al. Intermittent high glucose enhances ICAM-1, VCAM-1 and Eselectin expression in human umbilical vein endothelial cells in culture: the distinct role of protein kinase C and mitochondrial superoxide production. Atherosclerosis. 2005; 183: 259-267. doi: 10.1016/j.atherosclerosis.2005.03.015
30. Piconi L, Quagliaro L, Assaloni R, et al. Constant and intermittent high glucose enhances endothelial cell apoptosis through mitochondrial superoxide overproduction. Diabetes Metab Res Rev. 2006; 22: 198-203. doi: 10.1002/dmrr.613
31. Azuma K, Kawamori R, Toyofuku Y, et al. Repetitive fluctuations in blood glucose enhance monocyte adhesion to the endothelium of rat thoracic aorta. Arterioscler ThrombVasc Biol. 2006; 26: 2275-2280. doi: 10.1161/01.ATV.0000239488.05069.03
32. Mita T, Otsuka A, Azuma K, et al. Swings in blood glucose levels accelerate atherogenesis in apolipoprotein E-deficient mice. Biochem Biophys Res Commun. 2007; 358: 679-685. doi: 10.1016/j.bbrc.2007.04.118
33. Azuma K, Toyofuku Y, Iesaki T, et al. Acarbose, an a-glucosidase inhibitor, improves endothelial dysfunction in GotoKakizaki rats exhibiting repetitive blood glucose fluctuation. Biochem Biophys Res Commun. 2006; 345: 688-693. doi: 10.1016/j.bbrc.2006.04.090
34. Nalysnyk L, Hernandez-Medina M, Krishnarajah G. Glycaemic variability and complications in patients with diabetes mellitus: evidence from a systematic review of the literature. Diabetes Obes Metab. 2010; 12: 288-298. doi: 10.1111/j.1463- 1326.2009.01160.x.
35. Monnier L, Mas E, Ginet C, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA. 2006; 295: 1681-1687. doi: 10.1001/jama.295.14.1681
36. Ceriello A, Esposito K, Piconi L, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008; 57: 1349-1354. doi: 10.2337/db08-0063
37. Hu Y, Liu W, Huang R, Zhang X. Post challenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. Atherosclerosis. 2010; 210: 302-306. doi: 10.1016/j.atherosclerosis.2009.11.015
38. Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, HanefeldM. Post challenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care. 2000; 23: 1830-1834. doi: 10.2337/diacare.23.12.1830
39. Barbieri M, Rizzo MR, Marfella R, et al. Decreased ca rotid atherosclerotic process by control of daily acute glucose fluctuations in diabetic patients treated by DPP-IV inhibitors. Atherosclerosis. 2013; 227: 349-354. doi: 10.1016/j. atherosclerosis.2012.12.018
40. Wentholt IM, Kulik W, Michels RP, Hoekstra JB, DeVries JH. Glucose fluctuations and activation of oxidative stress in patients with type 1 diabetes. Diabetologia. 2008; 51: 183-190. doi: 10.1007/s00125-007-0842-6
41. Bragd J, Adamson U, Bäcklund LB, Lins PE, Moberg E, Oskarsson P. Can glycemic variability, as calculated from blood glucose self-monitoring, predict the development of complication in type 1 diabetes, over a decade? Diabetes Metab. 2008; 34: 612-616. doi: 10.1016/j.diabet.2008.04.005
42. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care. 2006; 29: 1486-1490. doi: 10.2337/dc06-0293
43. Kilpatrick ES, Rigby AS, Atkin SL. Mean blood glucose compared with HbA1c in the prediction of cardiovascular disease in patients with type 1 diabetes. Diabetologia. 2008; 51: 365-371. doi: 10.1007/s00125-007-0883-x
44. Moberg EA, Lins PE, Adamson UK. Variability of blood glucose levels in patients with type 1 diabetes mellitus on intensified insulin regimens. Diabetes Metab. 1994; 20: 546-552.
45. Gordin D, Ronnback M, Forsblom C, Mäkinen V, Saraheimo M, Groop PH. Glucose variability, blood pressure and arterial stiffness in type 1 diabetes. Diabetes Res Clin Pract. 2008; 80: e4-e7. doi: 10.1016/j.diabres.2008.01.010
46. Gimeno-Orna JA, Castro-Alonso FJ, Boned-Juliani B, LouArnal LM. Fasting plasma glucose variability as a risk factor of retinopathy in type 2 diabetic patients. J Diabetes Complications. 2003; 17: 78-81. doi: 10.1016/s1056-8727(02)00197-6
47. Zoppini G, Verlato G, Targher G, et al. Is fasting glucose variability a risk factor for retinopathy in people with type 2 diabetes? Nutr Metab Cardiovasc Dis. 2009; 19: 334-339. doi: 10.1016/j.numecd.2008.02.007
48. Cox DJ, Kovatchev BP, Julian DM, et al. Frequency of severe hypoglycemia in insulin-dependent diabetes mellitus can be predicted from self-monitoring blood glucose data. J Clin Endocrinol Metab. 1994; 79: 1659-1662. doi: 10.1210/jcem.79.6.7989471
49. Murata GH, Hoffman RM, Shah JH, Wendel CS, Duckworth WC. A probabilistic model for predicting hypoglycemia in type 2 diabetes mellitus: the Diabetes Outcomes in Veterans Study (DOVES). Arch Intern Med. 2004; 164: 1445-1450. doi: 10.1001/archinte.164.13.1445
50. Zoungas S, Patel A, Chalmers J, et al. ADVANCE Collaborative Group: Severe hypoglycemia and risks of vascular events and death. N Engl J Med. 2010; 363: 1410-1418. doi: 10.1056/ NEJMoa1003795
51. Yakubovich N, Gerstein HC. Serious cardiovascular outcomes in diabetes: the role of hypoglycemia. Circulation. 2011; 123: 342-348. doi: 10.1161/CIRCULATIONAHA.110.948489
52. Ceriello A, Novials A, Ortega E, et al. Evidence that hyperglycemia after recovery from hypoglycemia worsens endothelial function and increases oxidative stress and inflammation in healthy control subjects and subjects with type 1 diabetes. Diabetes. 2012; 61: 2993-2997. doi: 10.2337/db12-0224
53. Standards of medical care in diabetes 2015: summary of revisions. Diabetes Care. 2015; 8: S4. doi: 10.2337/dc15-S003